Outsourcing A Survival Strategy or a Tool for Speed to Market A Case Study - The biotech contract-manufacturing market has more than doubled in the last three years...from $1 billion to $3 billion

ADVERTISEMENT

Outsourcing A Survival Strategy or a Tool for Speed to Market A Case Study
The biotech contract-manufacturing market has more than doubled in the last three years...from $1 billion to $3 billion.


BioPharm International


CONCLUSION The decision to outsource depends partly on a company's size. For a start-up or small biotech firm, outsourcing is a must, but one that is not without risks and costs. For an established biotech company, outsourcing is an opportunity to:

  • Work with the best experts, giving them the possibility to work on industrial molecules and models.
  • Master the company's own process and improve understanding of its molecules.
  • Favor partnerships and generate innovative processes and products.
  • Generate additional scientific data to support complex requests from health authorities.
  • Achieve cost benefits, when the outsource partner is solid in its processes (microbial fermentation, small molecules, anti-sense peptides, etc.)
  • Reach platinum quality standards, establish new intellectual property protection, and raise the bar for the quality attributes of third-generation products.

ACKNOWLEDGEMENTS I wish to thank my colleagues Dr. Avinoam Kadouri and Dr. Gianni Baer for discussing with me Serono's Biotech Process Development Vision, and for their great help in the preparation of this manuscript.

Michele Antonelli, Ph.D., is senior vice president, manufacturing at Laboratoires Serono S.A., Zone Industrielle, CH-1267 Coinsins, Switzerland 0041.22.354.54.02, fax 0041.22.354.50.18,
.

REFERENCES 1. F. Kermani. The future looks outsourced. Pharmaceutical Technology Europe. Nov. 2004: 19-24.

2. Langer ES. Big shifts in outsourcing of biopharmaceutical manufacturing: half of manufacturers to outsource production by 2008. Genetic Engineering News. January 2004. Available at http:// http://www.bioplanassociates.com/knowledge/outsourcing.pdf.

RESOURCES 1. Booth R. Extending your enterprise with outsourcing. BioProcess International. October 10, 2003: 14-18.

2. Heffner S. Outsourcing in drug discovery. Contract Pharma. November-December 2003.

Available at http://www.contractpharma.com/NovDec033.htm.

3. Langer ES. Big shifts in outsourcing of biopharmaceutical manufacturing: half of manufacturers to outsource production by 2008. Genetic Engineering News. January 2004.

Available at http://bioplanassociates.com/knowledge/outsourcing.pdf.

4. McNear MS. The BioPharm International guide to selecting and working with a CMO. BioPharm International. October 2003(suppl) :1-34.

5. Miller J. All signs indicate a strong 2004 for contract services. Pharmaceutical Technology. December 2, 2003: 76-78.

6. F. Kermani. The future looks outsourced Pharmaceutical Technology Europe. Nov. 2004: 19-24.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

FDA Panel Unanimously Backs Secukinumab for the Treatment of Psoriasis
October 22, 2014
Roche to Expand and Improve its Basel Site
October 22, 2014
Pall ForteBio Releases Bioprocessing Contamination Detection Kit
October 22, 2014
EMA Works to Speed Up Ebola Treatment
October 20, 2014
Amgen Sues Sanofi and Regeneron over Patent for mAb Targeting PCSK9
October 20, 2014
Author Guidelines
Source: BioPharm International,
Click here